Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

18 Dec 2019

Anti-microbial agents with unique properties

Following the set of largely established US and EU guidelines which recommend the decolonisation of patients' noses of Staphylococcus aureus before surgery to prevent subsequent surgical site infections, Destiny recently reported the new Asia Pacific Society of Infection Control (APSIC) guidelines that are now harmonised with the US and EU positions. This is important for Destiny's first product - XF-73 which is currently in a US Phase IIb study for the prevention of post-surgical staphylococcal infections.

Download as a PDF file

Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 2nd Floor, Park House, 16-18 Finsbury Circus, London, EC2M 7EB

Website design & development by Breckenridge